Microsoft Word - NCI Manuscript

NCI Immunotherapy Agent Workshop Proceedings

Table 1. Final Rankings of Agents with High Potential for Use in Treating Cancer Rank* Agent

Rank*	Agent	Agent Category
1	IL-15	T-Cell Growth Factor
2	Anti-Programmed Death-1	**T-Cell Checkpoint Blockade
	(PD1)and/or anti–B7-H1 (PD1	Inhibitor
	Ligand)
3	IL-12	Vaccine Adjuvant
4	Anti-CD40 and/or CD40L	Antigen Presenting Cell
		Stimulator
5	IL-7	T-Cell Growth Factor
6	CpG	Vaccine Adjuvant
7	1-Methyl Tryptophan	Enzyme Inhibitor
8	Anti-CD137 (anti–4-1BB)	T-Cell Stimulator
9	Anti–TGF-beta	Signaling Inhibitor
10	Anti–IL-10 Receptor or Anti–	Suppression Inhibitor
	IL-10
11	Flt3L	Dendritic Cell Growth Factor/
		Vaccine Adjuvant
12	Anti-Glucocorticoid-Induced	T-cell Stimulator
	TNF Receptor (GITR)
13	CCL21 Adenovirus	T-Cell Attracting Chemokine
14	Monophosphoryl Lipid A	Vaccine Adjuvant
	(MPL)
15	Poly I:C and/or Poly ICLC	Vaccine Adjuvant
16	Anti-OX40	T-Cell Stimulator
17	Anti–B7-H4	T-Cell Checkpoint Blockade
		Inhibitor
18	Resiquimod and/or 852A	Vaccine Adjuvant
19	LIGHT and/or LIGHT vector	T-Cell Stimulator
20	Anti–Lymphocyte Activation	T-Cell Checkpoint Blockade
	Gene-3 (LAG-3)	Inhibitor

*Final rank was derived from voting by the workshop participants. The agents are listed according to median rankings. Means were used to break ties (see Table 4 for details).

**Anti-CTLA-4, a T-cell checkpoint blockade inhibitor, was considered of exceedingly high value but was not included on the list, as it is being produced by Bristol-Myers Squibb and Pfizer and is likely to be approved by the FDA within the foreseeable future.